Budget Impact Analysis
Cost-Comparison, Cost-Effectiveness, Utility, Benefit Analysis
-
Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness
-
Good research practices for comparative effectiveness research – defining, reporting & interpreting - Task Force Report Part I
-
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models
-
Estimating Health-State Utility for Economic Models in Clinical Studies
-
Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures
-
Transferability of Economic Evaluations Across Jurisdictions - Good research practices task force report
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations - ISPOR drug cost task force report - Part I
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective - ISPOR drug cost task force report - Part II
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective - ISPOR drug cost task force report - Part III
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and US Government Payers Perspectives ISPOR drug cost task force report - Part IV
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective - ISPOR drug cost task force report - Part V
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective - ISPOR drug cost task force report - Part VI
Multiple/Other types of Economic Evaluation
-
Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report 4
-
Economic Analysis of Vaccination Programs - Good Practices for Outcomes Research Task Force Report
-
Understanding Medication Compliance and Persistence from an Economics Perspective
Trial-Based Economic Evaluation
Value of Information
All Economic Evaluation Reports
Please Note: Reports are in reverse chronological order.
-
A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars
-
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)
-
Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report
-
Value of Information Analytical Methods - Report 2
-
Value of Information Analysis for Research Decisions - An Introduction Report 1
-
Understanding Medication Compliance and Persistence from an Economics Perspective
-
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models
-
Economic Analysis of Vaccination Programs - Good Practices for Outcomes Research Task Force Report
-
Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report 4
-
Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report 3
-
Cost-Effectiveness Analysis Alongside Clinical Trials II - Good research practices task force report
-
Principles of Good Practice for Budget Impact Analysis II
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations - ISPOR drug cost task force report - Part I
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective - ISPOR drug cost task force report - Part II
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective - ISPOR drug cost task force report - Part III
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and US Government Payers Perspectives ISPOR drug cost task force report - Part IV
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective - ISPOR drug cost task force report - Part V
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective - ISPOR drug cost task force report - Part VI
-
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report
-
Transferability of Economic Evaluations Across Jurisdictions - Good research practices task force report
-
Principles of Good Practice for Budget Impact Analysis I
-
Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials